PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1101
https://www.valueinhealthjournal.com/article/S1098-3015(19)33479-5/fulltext
Title :
PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33479-5&doi=10.1016/j.jval.2019.09.1101
First page :
Section Title :
Open access? :
No
Section Order :
10963